MEDULLARY THYROID CANCER. EXPERIENCE GBUZ OF THE REPUBLIC OF MORDOVIA "REPUBLICAN ONCOLOGICAL DISPENSARY"
Keywords:
medullary thyroid cancer; targeted therapy with vandetanib
Abstract
Medullary thyroid cancer (MTC) is a rare disease that accounts for 1.7% of all cases of malignant tumors of the thyroid gland. Disease in half of the cases diagnosed in the later stages, when systemic antitumor therapy is required. Recently, its high antitumor efficacy in the treatment disseminated MTC has demonstrated a new multikinase inhibitor, vandetanib. Goals and objectives of this study: 1. To assess the incidence of MTC in different age and gender groups in Republic of Mordovia. 2. Assess the overall 5-year survival rate depending on gender and stage in MTC in the Republic Mordovia.3. Assess the overall survival of disseminated medullary thyroid cancer in targeted therapy with vandetanib. The first experience in the Republic of Mordovia.References
1. Rumjancev P.O., Rumjanceva U.V. Targetnaja terapija vandetanibom medulljarnogo raka shhitovidnoj zhelezy u detej i podrostkov.
2. Mudunov A.M., Alymov Ju.V., Romanov I.S., Podvjaznikov S.O., Ignatova A.V. Jeffektivnost' vandetaniba v lechenii medulljarnogo raka shhitovidnoj zhelezy
3. Pod red. Kaprina A.D., Starinskogo V.V., Petrovoj G.V..Zlokachestvennye novoobrazovanija v Rossii v 2017 godu (zabolevaemost' i smertnost'. M.: MNIOI im. P.A. Gerceia, 2018. 250 s.
4. Wells S.A. Jr, Asa S.L., Dralle H. et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015;25(6):567-610. DOI: 10.1089/thy.2014.0335.
5. Howlader N., Noone A.M., Krapcho M. et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD. Available at:
https://seer. cancer.gov/csr/1975_2016.
6. Wells S.A., Jr. et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J
Clin Oncol. 2012; 30 (2): 134-41.
7. Robinson B.G. et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab.
2010; 95 (6): 2664-71.
8. Baudry C., Raepegaey A.C., Groussin L. Reversal of Cushing's syndrome by vandetanib in medullary thyroid carcinoma. N Engl J Med. 2013; 369 (6): 584-6.
9. Broniscer A. et al. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol. 2010; 28 (31): 4762-8.
10. Vandetanib (Vandetanibum) //server:registr lekarstvennyh sredstv Rossii. URL: https://www.rlsnet.ru/activesubstance/vandetanib-3179
11. Bel'cevich D.G., Vanushko V.Je., Rumjancev P.O. i dr. Rossijskie klinicheskie rekomendacii po diagnostike i lecheniju vysokodifferencirovannogo raka shhitovidnoj
zhelezy u vzroslyh, 2017 god. // Jendokrinnaja hirurgija. - 2017. - T. 11. - №1. - S. 6-27.
12. Kaprelsa. Instrukcija po medicinskomu primeneniju lekarstvennogo preparata. LP-002238 ot 11.01.2019.
13. Brierley J., Tsang R., Simpson W.J. et al. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in
local control. Thyroid 1996;6(4):305—10.
2. Mudunov A.M., Alymov Ju.V., Romanov I.S., Podvjaznikov S.O., Ignatova A.V. Jeffektivnost' vandetaniba v lechenii medulljarnogo raka shhitovidnoj zhelezy
3. Pod red. Kaprina A.D., Starinskogo V.V., Petrovoj G.V..Zlokachestvennye novoobrazovanija v Rossii v 2017 godu (zabolevaemost' i smertnost'. M.: MNIOI im. P.A. Gerceia, 2018. 250 s.
4. Wells S.A. Jr, Asa S.L., Dralle H. et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015;25(6):567-610. DOI: 10.1089/thy.2014.0335.
5. Howlader N., Noone A.M., Krapcho M. et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD. Available at:
https://seer. cancer.gov/csr/1975_2016.
6. Wells S.A., Jr. et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J
Clin Oncol. 2012; 30 (2): 134-41.
7. Robinson B.G. et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab.
2010; 95 (6): 2664-71.
8. Baudry C., Raepegaey A.C., Groussin L. Reversal of Cushing's syndrome by vandetanib in medullary thyroid carcinoma. N Engl J Med. 2013; 369 (6): 584-6.
9. Broniscer A. et al. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol. 2010; 28 (31): 4762-8.
10. Vandetanib (Vandetanibum) //server:registr lekarstvennyh sredstv Rossii. URL: https://www.rlsnet.ru/activesubstance/vandetanib-3179
11. Bel'cevich D.G., Vanushko V.Je., Rumjancev P.O. i dr. Rossijskie klinicheskie rekomendacii po diagnostike i lecheniju vysokodifferencirovannogo raka shhitovidnoj
zhelezy u vzroslyh, 2017 god. // Jendokrinnaja hirurgija. - 2017. - T. 11. - №1. - S. 6-27.
12. Kaprelsa. Instrukcija po medicinskomu primeneniju lekarstvennogo preparata. LP-002238 ot 11.01.2019.
13. Brierley J., Tsang R., Simpson W.J. et al. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in
local control. Thyroid 1996;6(4):305—10.
Published
2022-12-07
How to Cite
Almyashev, A.Z., and LarkinaА.А. 2022. “MEDULLARY THYROID CANCER. EXPERIENCE GBUZ OF THE REPUBLIC OF MORDOVIA "REPUBLICAN ONCOLOGICAL DISPENSARY"”. EurasianUnionScientists, December, 07-13. https://bio-med.euroasia-science.ru/index.php/Euroasia/article/view/833.
Section
Article
CC BY-ND
A work licensed in this way allows the following:
1. The freedom to use and perform the work: The licensee must be allowed to make any use, private or public, of the work.
2. The freedom to study the work and apply the information: The licensee must be allowed to examine the work and to use the knowledge gained from the work in any way. The license may not, for example, restrict "reverse engineering."
2. The freedom to redistribute copies: Copies may be sold, swapped or given away for free, in the same form as the original.
